A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc.
Takeda
IDEAYA Biosciences
Novartis
NeoTX Therapeutics Ltd.
HiFiBiO Therapeutics
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
Incyte Corporation
Actym Therapeutics, Inc.
Incyte Corporation
Incyte Corporation
Incyte Corporation
Instituto do Cancer do Estado de São Paulo
Memorial Sloan Kettering Cancer Center
Turnstone Biologics, Corp.
Sotio Biotech Inc.
Molecular Templates, Inc.
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
Pfizer
NGM Biopharmaceuticals, Inc
Massachusetts General Hospital
Rain Oncology Inc
University of Florida
Western Sydney Local Health District
Xencor, Inc.
Incyte Corporation
Calithera Biosciences, Inc
Augusta University
National Institutes of Health Clinical Center (CC)
MacroGenics
Shionogi Inc.
Incyte Corporation
Incyte Corporation
Incyte Corporation
Shenzhen BinDeBio Ltd.
Stanford University
Masonic Cancer Center, University of Minnesota
Novartis
Valerio Therapeutics
Valerio Therapeutics
University of Chicago
GlaxoSmithKline